Adze Biotechnology

Adze Biotechnology is a pre-clinical stage company developing a portfolio of systemically deliverable oncolytic immunotherapies for the treatment of cancers.

Adze Biotechnology Inc welcomes comments, questions and enquiries and lists its address as 2332 Galiano Street, Second Floor, Coral Gables, FL 33134.

Adze Biotechnology is developing a platform of immunotherapies that treat solid tumors and develop a robust anti-tumor immunity for patients.

Adze Biotechnology partners with King’s College London to advance a clinical trial for **ADZE1.C**, a therapy targeting hard-to-treat breast cancer. The collaboration aims to reprogram the tumor microenvironment and enhance systemic anti-tumor immunity. Dr. Paola Grandi, Adze’s Chief Scientific Officer, leads the effort.

Sep 2025Adze BiotechnologyNews article

Adze Biotechnology submits a Human Research Ethics Committee (HREC) application to Bellberry Limited for its Phase 1 clinical trial of **Adze1.C**, an oncolytic immunotherapy. The trial targets patients with **metastatic melanoma** in Australia. The company specializes in preclinical-stage biopharmaceutical innovations for cancer treatment.

Jun 2025Adze BiotechnologyNews article

Adze Biotechnology hires Dr. Paola Grandi to oversee its pre-clinical and translational research for systemically deliverable oncolytic immunotherapies. The company advances a pipeline targeting clinical development. Grandi brings expertise in PhD and MBA-accredited research.

Apr 2024Adze BiotechnologyNews article

ADZE Biotechnology secures a US patent for a novel recombinant adenovirus, expanding its portfolio of cancer therapeutics. The company develops treatments targeting a broad range of cancer indications through innovative biopharmaceutical approaches.

Sep 2023Adze BiotechnologyNews article